Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

[Treatment for prion disease: recent progress].

Tsuboi Y.

Rinsho Shinkeigaku. 2013;23(11):1255-7. Review. Japanese. No abstract available.

PMID:
24291948
2.

Human prion diseases: possible new directions in prophylaxis and therapy.

Oken RJ, McGeer PL.

Med Hypotheses. 1995 Mar;44(3):167-8. No abstract available.

PMID:
7609669
3.

New methods of preventing neurodegeneration? Lessons from prion diseases.

Beaulieu-Boire I, Fox SH.

Mov Disord. 2014 Jan;29(1):35. doi: 10.1002/mds.25782. Epub 2013 Dec 17. No abstract available.

PMID:
24347538
4.

[Prion diseases: disease diversity and therapeutics].

Doh-ura K.

Rinsho Shinkeigaku. 2004 Nov;44(11):855-6. Review. Japanese.

PMID:
15651313
5.

Neurodegenerative disease: Neurodegeneration halted with oral therapy in mice.

Jones B.

Nat Rev Neurol. 2013 Dec;9(12):658. doi: 10.1038/nrneurol.2013.226. Epub 2013 Nov 5. No abstract available.

PMID:
24189700
6.

Putting the downstream breaks on neurodegeneration?

McCarthy A, McKinley J, Lynch T.

Mov Disord. 2014 Feb;29(2):186. doi: 10.1002/mds.25744. Epub 2013 Dec 27. No abstract available.

PMID:
24375885
7.

Amyloidophilic compounds for prion diseases.

Teruya K, Kawagoe K, Kimura T, Chen CJ, Sakasegawa Y, Doh-ura K.

Infect Disord Drug Targets. 2009 Feb;9(1):15-22. Review.

PMID:
19200011
8.

Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice.

Moreno JA, Halliday M, Molloy C, Radford H, Verity N, Axten JM, Ortori CA, Willis AE, Fischer PM, Barrett DA, Mallucci GR.

Sci Transl Med. 2013 Oct 9;5(206):206ra138. doi: 10.1126/scitranslmed.3006767.

9.
10.

Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease.

Dealler S, Rainov NG.

IDrugs. 2003 May;6(5):470-8. Review. Erratum in: IDrugs. 2004 Jan;7(1):88.

PMID:
12789602
11.

A new PERKspective on neurodegeneration.

Scheper W, Hoozemans JJ.

Sci Transl Med. 2013 Oct 9;5(206):206fs37. doi: 10.1126/scitranslmed.3007641.

PMID:
24107775
12.

Perspectives on prion biology, prion disease pathogenesis, and pharmacologic approaches to treatment.

DeArmond SJ, Prusiner SB.

Clin Lab Med. 2003 Mar;23(1):1-41. Review.

PMID:
12733423
13.

Therapeutic approaches to prion diseases.

Rossi G, Salmona M, Forloni G, Bugiani O, Tagliavini F.

Clin Lab Med. 2003 Mar;23(1):187-208. Review.

PMID:
12733432
14.

Nanomedicine for prion disease treatment: new insights into the role of dendrimers.

McCarthy JM, Appelhans D, Tatzelt J, Rogers MS.

Prion. 2013 May-Jun;7(3):198-202. doi: 10.4161/pri.24431.

15.

Copper chelation delays the onset of prion disease.

Sigurdsson EM, Brown DR, Alim MA, Scholtzova H, Carp R, Meeker HC, Prelli F, Frangione B, Wisniewski T.

J Biol Chem. 2003 Nov 21;278(47):46199-202. Epub 2003 Sep 30.

16.

[Development of molecular target based-therapy for prion diseases].

Sakasegawa Y, Doh-ura K.

Brain Nerve. 2007 Apr;59(4):405-14. Review. Japanese.

PMID:
17447527
17.

Prion diseases--close to effective therapy?

Cashman NR, Caughey B.

Nat Rev Drug Discov. 2004 Oct;3(10):874-84. Review.

PMID:
15459678
18.

[Innovation of therapeutics and prophylaxis for prion diseases].

Doh-ura K.

Rinsho Shinkeigaku. 2009 Nov;49(11):946-8. Review. Japanese.

PMID:
20030256
19.

Prion diseases: Polythiophenes delay prion-induced neurodegeneration.

Crunkhorn S.

Nat Rev Drug Discov. 2015 Oct;14(10):679. doi: 10.1038/nrd4743. Epub 2015 Sep 21. No abstract available.

PMID:
26388230
20.

Calnexin inhibits thermal aggregation and neurotoxicity of prion protein.

Wang W, Chen R, Luo K, Wu D, Huang L, Huang T, Xiao G.

J Cell Biochem. 2010 Oct 1;111(2):343-9. doi: 10.1002/jcb.22698.

PMID:
20506117
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk